Company intelligence / Profile preview

튜링바이오

Seongnam-si, Gyeonggi-do, South Koreaturing.ac.uk ↗

Ownership: Private
Employees: ~21
Development stage: Preclinical

Overview

TuringBio develops AI-powered software platforms for screening, diagnosing, and digitally treating mental health conditions. Their products include omics-based diagnostic tools and clinical decision support systems. They also offer solutions for cardiovascular self-assessment. The company is active in government-supported R&D programs but does not have traditional clinical trial results as with pharmaceuticals.

Therapeutic areas: PsychiatryCardiovascular
Modalities: SoftwareDigital therapeuticsClinical decision support systemSaMD (Software as a Medical Device)Artificial intelligence
Industry: Digital Health Medical Devices

Partnerships

Government R&D programs (Ministry of Trade, Industry & Energy)Government R&D programs (Small & Medium Business Administration)

Beyond the preview

Go deeper on 튜링바이오.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 튜링바이오.

Explore the full profile